Expert Perspectives on Extended Follow-Up Data from ALPINE :

Chaitra S. Ujjani, MD examines extended follow-up data from the ALPINE trial, emphasizing noteworthy findings from the sensitivity and safety analyses recently presented at ASH 2023.

Related Keywords

Chaitras Ujjani , , Evolving Treatment Strategies , Chronic Lymphocytic Leukemia , Extended Follow Up Data , Cll , Btki , Venetoclax , Obinituzumab , Continuous Btki Therapy , Fixed Duration Therapy , Tumor Lysis Monitoring , Ibrutinib , Acalabrutinib , Zanubrutinib , Sequoia , Elevate Tn , Mash 2023 , Alpine , Elevate Rr , Aramaic , Treatment Naïve Cll , Newly Diagnosed Cll , Relapsed Cll , Refractory Cll , Efficacy , Safety , Real World Data , Treatment Resistance , Covalent Btki , Non Covalent Btki , Captivate , Flair , Hypertension , Atrial Fibrillation , Ventricular Arrythmia , Cardiovascular Aes , Treatment Selection , Mechanisms Of Resistance , Pirtobrutinib ,